Pfizer – Integrating Healthcare with Deep Tech

Healthcare industry is transforming at a very rapid speed. Pharma as a sector is moving towards disruption. Medical findings are merging with deeper technologies for better understanding human anatomy and finding innovative solutions.  DNA sequencing, Gene Editing and Artificial Intelligence are coming together to cure various human decease which were unimaginable in the past. Medicine industry is improving with the intersection of technological solutions and this is greatly changing the world of medicine.

Pfizer is third largest MNC company operating in India. It has 150 products across 15 therapeutic areas. During 2021, Pfizer has changed its brand identity and its emblem is representation of transformative power of science. Pfizer Global CEO, Mr Albert Bourla is one of the most powerful CEO and his vision is to use the power of science to cure and prevent disease, instead of treating the disease. 

Government is undertaken systemic policy reforms for boosting the healthcare sector in India and for inviting FDI. Production linked incentive (PLI) schemes is a big policy support in this direction and is intending to strengthen domestic pharmaceuticals Industry by providing production linked incentive.

Company is a World leader in the vaccine space. In India it has a strong presence in the area of Inflammation and Immunology for treating disease like Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Psoriasis and Internal Bowel Diseases. Company has Internal Medicine (IM) team. The team is responsible for framing mission for developing strategies for delivering sustainable, market-beating growth.

Artificial Intelligence, Big Data, Remote Monitoring, 3D Printing, are some of the technologies that are at the forefront of driving change in the medicine and healthcare industry. Bones and Artificial Organs are being reproduced using 3D Printing. Big data is being used for analysing medical and healthcare Industry. AI algorithms are continuously adjusting to the deep learning emanating from big data finding. Apps are monitoring vital health parameters on the real time and patients are availing consultation based from remote areas using remote monitoring technologies.

During Last 10 years, its sales has increase from Rs 1017 Crores ( Mar 2012) to Rs 2190 Crore (March 2021).  Its PBT has increased for Rs 278 Crores ( Mar 2012) to Rs 669 Crore (March 2021). Company has been successfully maintaining Its PBT margin abave 20% for last 10 years. During March 2021, company had a margin of approx. 29%.  According to the estimates projected by Indian Economic Survey 2021, by the next decade, Indian pharmaceutical market is expected to grow by US$ 65 billion by 2024 and may reach the size of  US$ 120-130 billion by 2030.

Pfizer has a strong presence in the Respiratory portfolio. It has strong brands for treating Cough, Oral Corticosteroids and Smoking Cessation therapies. Its flagship brand Corex is a household name in India. Besides this Pfizer has a strong portfolio in the category of Vitamins, Neuroscience and Cardiovascular, Women’s Healthcare, Pain and inflammation portfolio. Company is increasing its reach trough digital market, in addition to the regular channels of sales. On the innovations ide, Pfizer has created a platform for driving breakthrough innovations, known as Breakthrough Change Accelerator (BCA). BCA is a platform in the nature of an incubation sandbox for building innovative and cutting-edge health care solutions for transforming the healthcare industry by usage of deep tech like Artificial Intelligence (AI).

Next wave of growth in pharma sector will be led by the Companies which are adopting deep tech in their innovation model. Pfizer is at the forefront of Innovation and is well positioned to create long term value for its stakeholders.

Bureau Galactik Views

Related articles